Isomorphic Labs raises $5B to advance drug candidates toward clinical trials
AI drug discovery company Isomorphic Labs has raised $5 billion in a Series C round as it seeks to take drug candidates to clinical trials. It plans to keep developing its drug-design engine and expand into more types of medicine. The company says its oncology and immunology programs have yielded positive preclinical results; those results do not establish how the candidates will perform in human trials.